Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke

Completed

Phase 2 Results N/A

Summary of Purpose

Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to know if it causes a reduction of glutamate-mediated excitotoxicity.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 October 2016.

1 Mar 2015 21 Apr 2015 1 Dec 2015 1 Dec 2015 1 Oct 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts